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Background: In patients with ovarian cancer relapsing at least 6 months after end of primary treatment, the
addition of paclitaxel to platinum treatment has been shown to improve survival but at the cost of significant
neuropathy. In the first line setting, the carboplatin-docetaxel combination was as effective as the combination of
carboplatin and paclitaxel but with less neurotoxicity. This study was initiated to evaluate the feasibility of carboplatin
with docetaxel as second line treatment in patients with ovarian, peritoneal or fallopian tube cancer.
Methods: Patients with stage IC-IV epithelial ovarian, peritoneal or fallopian tube cancer were enrolled at the first
relapse after at least 6 months since completion of the first line treatment. Docetaxel 75 mg/m2 was given as an
one hour IV infusion followed immediately by carboplatin (AUC = 5) given as a 30–60 min. IV infusion on day 1
and repeated every 3 weeks for 6–9 courses. Primary endpoint was toxicity; secondary endpoints were response
rate and the time to progression.
Results: A total of 74 patients were included. Of these, 50 patients received 6 or more cycles, 13 received 3–5
courses and 11 received less than 3 courses. A total of 398 cycles were given. Grade 3/4 neutropenia was seen in
80% (59 of 74) patients with an incidence of febrile neutropenia of 16%. Grade 2/3 sensory peripheral neuropathy
occurred in 7% of patients, but no grade 4 sensory peripheral neuropathy was observed. Sixty patients were
evaluable for response. The overall response rate was 70% with 28% complete responses in the response
evaluable patient population. Median progression-free survival was 12.4 months (95% CI 10.4-14.4).
Conclusions: The three-weekly regimen of docetaxel in combination with carboplatin was feasible and active as
second-line treatment of platinum-sensitive ovarian, peritoneal and Fallopian tube cancer. The major toxicity was
neutropenia, while the frequency of peripheral neuropathy was low.
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Epithelial ovarian cancer, the second most common
gynecological malignancy, is the fifth leading cause of
cancer-related death in women in the United States [1].
Most patients present with disease in advanced stage.
Surgery followed by chemotherapy with carboplatin and
paclitaxel has become the standard treatment [2]. Although
most patients achieve a complete response, the majority
will suffer a relapse and eventually die from the disease.
Relapses occurring ≥ 6 months after end of first line treat-
ment are considered platinum sensitive and are advised to
be treated with a platinum based regimen [3].
The ICON4/AGO-Ovar-2.2 study [4] demonstrated im-
proved survival by adding paclitaxel to a platinum agent in
patients with platinum sensitive recurrent ovarian cancer.
However, this combination is associated with significant
neurotoxicity [5]. Furthermore, many women will suffer
from persistent neuropathy from the initial taxane con-
taining regimen, making re-treatment with paclitaxel a
difficult endeavor [6]. Studies have shown that patients
report motor neuropathy as the most unpleasant adverse
effect of treatment [7] and the development of neuropathy
is a major factor impairing quality of life [8], which can
lead to early treatment discontinuation.
The combination of carboplatin and docetaxel was found
to be associated with similar survival as the combination of
carboplatin and paclitaxel in first line treatment of ovarian
cancer [9]. The combination of carboplatin and docetaxel
caused considerably less neurotoxicity than carboplatin-
paclitaxel with grade ≥ 2 neurosensory toxicity in 11%
versus 30% and grade ≥ 2 neuromotor toxicity in 3%
versus 7% of patients. The positive clinical experiences
with carboplatin plus docetaxel provide a strong basis
for continued investigation of platinum/docetaxel based
chemotherapy in the management of advanced ovarian
cancer.
Only a few studies have evaluated docetaxel in com-
bination with carboplatin as second-line combination
chemotherapy for ovarian cancer [10,11]. A phase II trial
of docetaxel and carboplatin in recurrent platinum-
sensitive ovarian, peritoneal or Fallopian tube cancer with
a platinum-free interval of at least 6 months [10] enrolled
25 patients. Docetaxel 75 mg/m2 followed by carboplatin
(AUC5) on day 1 was given every 3 weeks for 6 courses.
Among the 23 evaluable patients, the overall response
rate was 72% with 16 (64%) complete and 2 (8%) partial
responses. Sensory neuropathy grade 1/2 was observed
in 10 patients (40%), no grade 3/4 sensory or motor
neuropathy was observed. Neutropenia was the most
frequent grade 3/4 hematologic toxicity occurring in 15
patients (60%), but no episodes of febrile neutropenia
was observed in this trial.
In order to evaluate the combination of carboplatin and
docetaxel as treatment of platinum-sensitive recurrentovarian, peritoneal and Fallopian tube cancers, the Nordic
Society of Gynecologic Oncology (NSGO) performed a
phase II trial in patients with a relapse ≥ 6 months after
completion of first line treatment.Methods
Study patients
Eligibility criteria included age ≥ 18 years, a histologically
verified diagnosis of epithelial ovarian carcinoma, peri-
toneal or Fallopian tube cancer and disease progression
6 months or later after completion of first line treatment
with carboplatin and paclitaxel. Measurable disease ac-
cording to Response Evaluation Criteria in Solid Tumors
(RECIST 1.0) or CA-125 assessable disease according to
Gynecologic Cancer Inter Group (GCIG) criteria [12,13].
Other key eligibility criteria included a WHO perform-
ance status of 0–2 and adequate bone marrow, renal and
hepatic function. Patients with pre-existing peripheral
neuropathy (National Cancer Institute Common Toxicity
Criteria for Adverse Events [NCI-CTCAE version 2] >
grade 1) were excluded.
The study was designed and carried out in accordance
with good clinical practice, the declaration of Helsinki
and national laws. The local ethics committee at each
participating center approved the study (Danmark: Den
Videnskabsetiske komite or Vejle og Fyns Amter; Norway:
Regional Committees For Medical and Health Research
Studies; Finland: Regional ethical review board). All patients
gave their written informed consent before study entry.
Study design
Patients were prospectively recruited into this single
arm study. The main endpoint was toxicity, with special
emphasis on the frequency of febrile neutropenia. Second-
ary endpoints were response rate and progression free
survival. Treatment was given as a combination of doce-
taxel 75 mg/m2 intravenously followed by carboplatin
(AUC = 5) based on the Calvert formula [14] using the
glomerular filtration rate calculated according to the
method of Cockroft and Gault [15]. Treatment was
repeated every 3 weeks for 6–9 cycles unless progres-
sive disease or unacceptable toxicity occurred. Written
informed consent in compliance with the recommenda-
tions of the Declaration of Helsinki was obtained in all
cases before inclusion. The study was registered with
ClinicalTrials.gov (NCT02026921).
Treatment plan and dose modification
All patients received premedication with corticosteroid
and a serotonin receptor antagonist. With bone marrow
recovery within 28 days, the patients were retreated with
full dose of docetaxel. With recovery within 29–35 days,
the dose of docetaxel was reduced to 60 mg/m2. When
Table 1 Demographics and tumor characteristics
Characteristics (n = 74) No. of patients (%)
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patient went off study. Only one dose reduction of
docetaxel was allowed. In case of febrile neutropenia
(ANC <1 × 10 9 /L and fever ≥ 38.5°C) the dose of doce-
taxel was reduced to 60 mg/m2 and the dose of carbopla-
tin to AUC4 in the subsequent cycles. Use of granulocyte
colony stimulating factor (G-CSF) was not allowed on a
routine basis, but could be used at the discretion of the
investigator in case of myelotoxicity.
In case of peripheral neuropathy or oedema (grade 2) or
gastrointestinal toxicity (diarrhoea, nausea, and vomiting
grade 3) treatment was delayed until recovery for a
maximum of 2 weeks and patients were retreated with
docetaxel 60 mg/m2. In case of grade 3/4 peripheral
neuropathy (motor or sensory), oedema grade 3/4 or
any non-hematological toxicity grade 4, patients went











Well differentiate 11 (15)
Moderate well differentiate 21 (28)









Response to firs line therapy
Complete response (CR) 38 (51)
Partial response (PR) 8 (11)Clinical evaluation and assessments
Baseline assessments were performed within 14 days prior
to study entry and included: hematological tests (full blood
count and differential white cell count); biochemical profile
(CA125, total serum bilirubin, alkaline phosphatases,
AST or ALT and creatinine); physical examination (WHO
performance status, weight, and height); radiological exam-
ination including chest X-Ray, abdominal-pelvic CT-scan.
Other radiological examinations as indicated.
During chemotherapy, hematological tests were per-
formed before each infusion and again on day 14 +/− 2
days. Biochemical tests and physical examination were
performed before each infusion. Measurement of all
lesions reported at baseline and screening for new lesions
were performed every 9th week with the same method as
used at baseline. Evaluation of response was done accord-
ing to RECIST 1.0 criteria. Adverse events were graded
using NCI-CTCAE version 2.
Serious adverse events (SAEs) occurring within 30 days
after chemotherapy were reported. Clinical follow-up was
performed every 3 months for the first 2 years, every 6
months the following year and annually thereafter,
respectively. Responses were verified at the first follow up
visit when applicable. During follow-up, CA125 was mea-
sured at each visit until progression. All patients (includ-
ing patients who were withdrawn from the protocol
treatment) were followed according to this scheme.Stable disease (SD) 2 (3)
Non-evaluated disease (NED) 26 (35)
Time from end of first line
chemotherapy to relapse
Median months (range) 15.7 (6-80.9)
Relapse between 6 to 12 months 26 (35.1%)
Relapse >12 months 48 (64.9%)Statistical methods
Progression-free survival was defined as time from regis-
tration to progression or death by any cause. Survival
curves were determined using Kaplan-Meier estimates.
The sample size was chosen to allow for a relative nar-
row confidence interval for the frequency of febrile
neutropenia.Results
Patient characteristics and treatments
A total of 74 patients were enrolled into this phase II
trial by 6 member institutions of NSGO from August
2004 to August 2005. Patient demographics are outlined
in Table 1. The median age was 61 years (range, 27–79
years). The majority of patients had ovarian cancer
(93%), FIGO stage III/IV disease (85%), and 60 patients
(81%) had serous type histology. A total of 398 cycles
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13 received 3–5 courses and 50 received at least 6 courses.
The reason for withdrawal before completion of the
planned 6 cycles were progression in 4 patients, allergic
reaction to carboplatin in 10, allergic reaction to docetaxel
in 1, febrile neutropenia in 2, impaired performance status
in 1, increased liver enzymes in 1, other toxicities in 4
and withdrawal of consent in 1 patient. Of patients who
received only 1–2 courses, 1 stopped due to early pro-
gression, 2 due to toxicity, 1 due to allergic reaction to
docetaxel and 7 due to allergic reaction to carboplatin.
Dose reduction of docetaxel was done in 26 of 398
cycles (7%, 14 patients) and dose reduction of carbopla-
tin was done in 5 of 398 cycles (1%, 4 patients). In total,
dose reduction was done in 16 of 74 patients (22%).
Cycle prolongation of up to one week occurred in 20
patients due to the following reasons: neutropenia 5
patients, neutropenia and thrombocytopenia 1 patient,
reduced performance status 3 patients, increased liver
enzymes 1 patient, oedema 1 patient, intercurrent disease
4 patients and logistic reasons 5 patients. One patient had
a cycle prolongation of more than one week due to an
intercurrent disease.
Toxicity
Non-hematologic toxicities of docetaxel-carboplatin are
summarized in Table 2. Significant non-hematologic toxic-
ities were uncommon, and overall the combination wasTable 2 Non-hematologic toxicity
Grade of toxicity (NCI-CTVAE grade v2.0)
1 2 3 4
n(%) n(%) n(%) n(%)
Arthralgia 23(31) 2(3) 1(1) 0(0)
Myalgia 29(39) 4(5) 0(0) 0(0)
Nausea 36(49) 12(16) 4(5) 0(0)
Vomiting 9(12) 7(9) 4(5) 0(0)
Mucositis/Stomatitis 21(28) 13(18) 0(0) 0(0)
Neurohearing 3(4) 1(1) 0(0) 0(0)
Neuromotor 2(3) 1(1) 0(0) 0(0)
Neurosensory 34(46) 4(5) 1(1) 0(0)
Edema 13(18) 4(5) 0(0) 0(0)
Fatigue 24(32) 18(24) 0(0) 0(0)
Change of taste 13(18) 4(5) 0(0) 0(0)
Anorexia/weight loss 2(3) 1(1) 0(0) 0(0)
Diarhoe 6(8) 0(0) 0(0) 0(0)
Nail changes 6(8) 5(7) 0(0) 0(0)
Rash 2(3) 1(1) 0(0) 0(0)
Epiphora 1(1) 2(3) 0(0) 0(0)
NCI-CTCAE: National Cancer Institute Common Toxicity Criteria for
Adverse Events.well tolerated. Treatment-related sensory peripheral neur-
opathy was low, with grade 2 in 4 patients and grade 3 in
1 patient. Three patients (4%) suffered grade 1/2 motor
peripheral neuropathy and none had grade 3/4.
Nausea, arthralgia/myalgia, mucositis/stomatitis and fa-
tigue were the most common non-hematologic toxicities,
but rarely severe. Grade 3 emesis was reported in 4
patients (5%) and grade 3 arthralgia in one patient (1%).
Grade 2 fatigue was reported in 18 patients (24%). Edema
was not a significant clinical problem. Increased fluid
retention grade 2 that did not require diuretic therapy was
reported by 4 patients (5%).
Hematologic toxicity is presented in Table 3. Neutro-
penia and leukopenia were most frequently reported.
The incidence of grade 3 and 4 neutropenia was 27%
(20/74) and 53% (39/74), respectively. Febrile neutro-
penia was reported in 12 patients (16%), in 5 of these in
the first course and in 3 in the second or third course.
In 6 patients (8%) G-CSF was used after an episode of
febrile neutropenia. Anemia was quite common but
mild. Grade 1 /2 anemia occurred in 64 patients (86%),
no grade 3 /4 anemia was reported. Nine patients (12%)
received blood transfusion and 1 patient (1%) received
erythropoietin support. Thrombocytopenia was rare,
with only 7 patients (9%) experiencing this toxicity of
whom 2 (3%) had grade 4.
Response and survival
Evaluation of response was performed in 61 patients
with measurable disease. Seventeen achieved a complete
response, 26 a partial response, 8 had stable disease and
10 had progression during treatment. The overall response
rate was 70% (43/61) in the efficacy-evaluable patient
population and 58% (43/74) in the intention to treat popu-
lation. The median progression-free survival in the ITT
population was 12.4 months (95% CI 10.4-14.4) as shown
in Figure 1.
Discussion
Overall the combination was well tolerated. Most cases of
arthralgia and myalgia were mild. The most unpleasant
side effects were mucositis/stomatitis grade 2 and fatigueTable 3 Hematologic toxicity
Grade of toxicity (NCI-CTVAE grade v2.0)
1 2 3 4
n(%) n(%) n(%) n(%)
Leucocytopenia 15(20) 27(36) 21(28) 3(4)
Neutropenia 3(4) 5(7) 20(27) 39(53)
Febrile neutropenia 0(0) 0(0) 12(16) 0(0)
Thrombocytopenia 4(5) 1(1) 0(0) 2(3)
Anemia 44(59) 20(27) 0(0) 0(0)
NCI-CTCAE: National Institute Common Toxicity Criteria for Adverse Events.
Figure 1 Total progression-free survival in the intention-to-treat population (n = 74).
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frequency of neurotoxicity was low. Neuropathy grade 2
and 3 was reported in only 6% and 1% of patients, respect-
ively. This low frequency is in line with the findings in
other studies on the combination of carboplatin and doce-
taxel in relapsed ovarian cancer [10,16,17]. In contrast, up
to 27% moderate or severe neurological toxicity (≥ grade
2) has been observed in studies with the platinum-
paclitaxel combination in recurrent ovarian, peritoneal
and fallopian tube cancer [4,18]. The study was restricted
to patients with a maximum of grade 1 neurotoxicity at
recruitment, thus we cannot evaluated how this combin-
ation would influence on more pronounced preexisting
neuropathy. Unlike neuropathy induced by paclitaxel,
which may manifest early during treatment, docetaxel-
induced neutropathy generally does not appear until
cumulative dose of docetaxel exceeds 600 mg/m2 [17]. As
docetaxel is associated with less neurotoxicity than pacli-
taxel and generally is delivered as a convenient 1-hour
infusion, suitable for out-patient administration, it mightbe a good substitution for paclitaxel in order to decrease
neuropathy in the treatment of recurrent ovarian cancer.
As anticipated, neutropenia was the major toxicity in
the present study, occurring with grade 3/4 in 80% of all
patients and was the main reason for dose reductions.
Previous studies have demonstrated a high incidence of
severe (grade 3/4) neutropenia when combining doce-
taxel with carboplatin in the treatment of ovarian and
other gynecologic malignancies. A range of 33.3%-94%
has been reported in first line [9,19,20], and of 60%-98%
in second-line chemotherapy [10,16].
Febrile neutropenia was reported in 11% of patients in
the SCOTROC study [9] on first line chemotherapy.
This did not compromise dose delivery or safety. In the
present study, a higher frequency of febrile neutropenia
(16%) was observed as could be expected in the second
line setting. Febrile neutropenia usually occurred early in
the treatment. The frequency of febrile neutropenia seen
in our and another study [18] call for prophylactic use
of G-CSF support when this combination is used in
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G-CSF in older patients (> 65 years-old) and in those
with comorbidities if the risk of febrile neutropenia
exceeds 10% [21]. In accordance with other studies
[9,10,19], thrombocytopenia was infrequent and usually
mild. We observed only two patients with thrombocy-
topenia grade 4. The low rate of thrombocytopenia indi-
cates that docetaxel may have a thrombocyte sparing effect
when combined with paclitaxel.
In first line treatment of ovarian cancer, the combin-
ation of carboplatin and docetaxel has been found as
effective as the carboplatin-paclitaxel combination [9].
Although inter-study comparisons are problematic, the
findings of an overall response rate of 70% in the response
evaluable population and a median progression free sur-
vival of 12.4 months in the present study are in line with
the findings in studies using carboplatin in combination
with either paclitaxel or pegylated liposomal doxorubicin
in second line treatment of ovarian cancer [4,18,22].
The relative high frequency of carboplatin hypersensi-
tivity reactions is in accordance with previous reports
[16,18,23] on repeated treatment with carboplatin in
patients with relapsed ovarian cancer. It is of interest that
this frequency seemed to be lower when these women were
treated with the combination of carboplatin and pegylated
doxorubicin compared to carboplatin and paclitaxel [18].
Conclusions
The 3 weekly regimen of docetaxel in combination with
carboplatin was feasible and active in second-line treat-
ment for platinum-sensitive ovarian, peritoneal and fal-
lopian tuber cancer with a low frequency of peripheral
neuropathy. The major toxicity was neutropenia.
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